Key result
Aldosterone antagonists face Cochrane review protocol assessing benefits and harms in dialysis patients.
Why the study?
Do aldosterone antagonists provide benefits and reduce harms compared to placebo or standard care in people with ESKD requiring haemodialysis or peritoneal dialysis?
Do aldosterone antagonists provide benefits and reduce harms compared to placebo or standard care in people with ESKD requiring haemodialysis or peritoneal dialysis?
This is a protocol for a Cochrane Review assessing the benefits and harms of aldosterone antagonists in patients with ESKD requiring dialysis.
No takes yet. Share an insight, caveat, or question.
Protocol leaves aldosterone antagonist use in dialysis undecided; forthcoming Cochrane review will synthesize benefits and harms.
Hasegawa et al. (2018) studied this question. Aldosterone antagonists are the subject of a Cochrane Review protocol assessing their benefits and harms compared to standard care in patients with end-stage kidney disease requiring dialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: